Articles

Listed below are scientific articles related to polycythemia vera, essential thrombocythemia, and myelofibrosis. For your convenience, we have provided links to these abstracts and articles. If a link is no longer available or if you are unable to download an article, please contact the publisher directly to obtain this information.

2019

MF
Anand K, Burns EA, Ensor J, Rice L, Pingali SR. Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review. Clin Lymphoma Myeloma Leuk. 2019 Aug 26. pii: S2152-2650(19)31325-4. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31325-4/fulltext
Barbui T, Thiele J, Gisslinger H, et al. Comments on pre-fibrotic myelofibrosis and how should it be managed. Br J Haematol. 2019;186:358-360. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15840
Barbui T, De Stefano V, Falanga A, et al. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer J. 2019;9:61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687826/
Blair HA. Fedratinib: First Approval. Drugs. 2019 Oct;79:1719-1725. doi: 10.1007/s40265-019-01205-x. https://link.springer.com/article/10.1007%2Fs40265-019-01205-x
Bose P, Alfayez M, Verstovsek S. New concepts of treatment for patients with myelofibrosis. Curr Treat Options Oncol. 2019;20:5. doi: 10.1007/s11864-019-0604-y. https://link.springer.com/article/10.1007%2Fs11864-019-0604-y
Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2019 Oct 19. doi: 10.1007/s12185-019-02758-z. [Epub ahead of print]. https://link.springer.com/article/10.1007%2Fs12185-019-02758-z
Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019;60:1176-1185. doi: 10.11406/rinketsu.60.1176. https://www.jstage.jst.go.jp/article/rinketsu/60/9/60_1176/_article
Cottin L,  Riou J, Orvain C, et al. Sequential mutational evaluation of CALR‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 2019; 2019 Nov 11. doi: 10.1111/bjh.16276. [Epub ahead of print]. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16276
Cruz NM, Gergis U, Silver RT. Myelofibrosis: best practices, controversies and 2019 update. Expert Rev Hematol. 2019 Nov 30:1-14. doi: 10.1080/17474086.2020.1691519. [Epub ahead of print]. https://www.tandfonline.com/doi/abs/10.1080/17474086.2020.1691519?journalCode=ierr20
Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long
Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. Curr Hematol Malig Rep. 2019;14:460-468. doi: 10.1007/s11899-019-00538-4. https://link.springer.com/article/10.1007%2Fs11899-019-00538-4
Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133:790-794. doi: 10.1182/blood-2018-11-876888. Epub 2019 Jan 2. https://ashpublications.org/blood/article-abstract/133/8/790/260592/Luspatercept-for-the-treatment-of-anemia-in?redirectedFrom=fulltext
Gangat N, Marinaccio C, Swords R, et al. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long
Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext
Kuykendall AT, Talati C, Padron E. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25625
Maekawa T, Kato S, Kawamura T, et al. Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood. 2019;134:814-825. doi: 10.1182/blood.2019000051. Epub 2019 Jul 3. https://ashpublications.org/blood/article-abstract/134/10/814/260635/Increased-SLAMF7high-monocytes-in-myelofibrosis?redirectedFrom=fulltext
Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507
Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol. 2019;17:299-307. https://www.ncbi.nlm.nih.gov/pubmed/31188809
Masarova L, Bose P, Verstovsek S. The rationale for immunotherapy in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2019;14:310-327. https://link.springer.com/article/10.1007%2Fs11899-019-00527-7
Mascarenhas J, Marcellino BK, Lu M, et al. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Leuk Res. 2019;88:106272. doi: 10.1016/j.leukres.2019.106272. [Epub ahead of print]. https://www.sciencedirect.com/science/article/pii/S0145212619307179?via%3Dihub
Mascarenhas J, Baer MR, Kessler C, et al. Phase II trial of lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2019;60:1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. https://www.tandfonline.com/doi/abs/10.1080/10428194.2018.1532509?journalCode=ilal20
Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/
DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN6, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442950/
McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5. https://www.bbmt.org/article/S1083-8791(19)30418-5/fulltext
Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/
Mesa RA, Su Y, Woolfson A, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes. 2019;17:61. doi: 10.1186/s12955-019-1121-1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460742/
Mesa RA. Proactive steps to optimize the management of polycythemia vera and myelofibrosis. Clin Adv Hematol Oncol. 2019;17:475-477.
Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y
Mora B, Rumi E, Guglielmelli P, et al. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019;8:4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675726/
Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol. 2019;84:891-898. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768916/
Palmer J, Kosiorek HE, Wolschke C, et al. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019;25:2267-2273. doi: 10.1016/j.bbmt.2019.07.001. Epub 2019 Jul 6. https://www.bbmt.org/article/S1083-8791(19)30433-1/fulltext
Sapre M, Tremblay D, Wilck E, et al. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Sci Rep. 2019; 9: 16609. Published online 2019 Nov 12. doi: 10.1038/s41598-019-53056-x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851362/
Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O’Mahony A. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS One. 2019;14:e0222944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764664/
Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext
Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext
Tremblay D, King A, Li L, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2019 Nov 12:1-8. doi: 10.1080/10428194.2019.1688323. [Epub ahead of print]. https://www.tandfonline.com/doi/abs/10.1080/10428194.2019.1688323?journalCode=ilal20
Tremblay D, Putra J, Vogel A, et al. The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/
Vallapureddy RR, Mudireddy M, Penna D, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019;9:12. doi: 10.1038/s41408-019-0175-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347609/
Winton EF. Myelofibrosis management after ruxolitinib failure. Clin Lymph Myeloma Leuk. 2019;19(supplement 19):S12-S14. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31174-7/fulltext
Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living With MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/
PV
Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719465/
Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019 Oct 18;10:359-371. doi: 10.2147/JBM.S189922. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805785/
Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long
Foltz L, Pica GM, Zerazhi H, et al. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leuk Lymphoma. 2019 Jul 30:1-10. doi: 10.1080/10428194.2019.1636985. [Epub ahead of print] https://www.tandfonline.com/doi/abs/10.1080/10428194.2019.1636985?journalCode=ilal20
Gangat N, Marinaccio C, Swords R, et al. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long
Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext
Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19:579-584.e1. doi: 10.1016/j.clml.2019.06.001. Epub 2019 Jun 13. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)30312-X/fulltext
Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071-1082. doi: 10.1007/s00277-019-03625-x. Epub 2019 Mar 8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469649/
Ianotto JC, Curto-Garcia , Lauermanova M1, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104:1580-1588. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669170/
Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507
Masarova L, Bose P, Verstovsek S. The Rationale for immunotherapy in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2019;14:310-327. https://link.springer.com/article/10.1007%2Fs11899-019-00527-7
Mascarenhas J, Kosiorek H, Prchal J, et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019;33:2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. https://www.nature.com/articles/s41375-019-0524-7
Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/
Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/
Mesa RA. Proactive steps to optimize the management of polycythemia vera and myelofibrosis. Clin Adv Hematol Oncol. 2019;17:475-477.
Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y
Parasuraman S, Yu J, Paranagama D, et al. Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data. Ann Hematol. 2019;98:2533-2539. doi: 10.1007/s00277-019-03793-w. Epub 2019 Sep 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848033/
Ritchie EK. Drug development challenges in polycythemia vera. Blood. 2019;134:495-496. doi: 10.1182/blood.2019001875. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019001875
Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treat Res. 2019;179:159-178. https://link.springer.com/chapter/10.1007%2F978-3-030-20315-3_11
Shaw G, Berg R. Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera. Clin Med Res. 2019 Oct 3. pii: cmr.2019.1483. doi: 10.3121/cmr.2019.1483. [Epub ahead of print] http://www.clinmedres.org/content/early/2019/09/30/cmr.2019.1483.long
Spivak JL. How I treat polycythemia vera. Blood. 2019;134:341-352. doi: 10.1182/blood.2018834044. Epub 2019 May 31. https://ashpublications.org/blood/article-abstract/134/4/341/260695/How-I-treat-polycythemia-vera?redirectedFrom=fulltext
Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext
Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133-143. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25303
Tremblay D, Putra J, Vogel A, et al. The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/
Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-1509. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000428
Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/
ET
Baerlocher GM, Haubitz M, Braschler TR, et al. Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia. Blood Adv. 2019;3:3724-3728. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880912/
Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719465/
Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long
Gangat N, Marinaccio C, Swords R, et al. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long
Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext
Geringer J, Fenderson J, Osswald M. Essential Thrombocythemia Complicated by Occlusive Thrombosis of the Abdominal Aorta. Case Rep Hematol. 2019 Mar 26;2019:9454501. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458875/
Gisslinger H, Buxhofer-Ausch V, Hodisch J, et al. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol. 2019;185:691-700. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594023/
Ianotto JC, Curto-Garcia , Lauermanova M1, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104:1580-1588. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669170/
Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507
Masarova L, Verstovsek S. Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs. 2019;24:93-105. Epub 2019 May 14. https://www.tandfonline.com/doi/abs/10.1080/14728214.2019.1615437?journalCode=iemd20
Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/
Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/
Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y
Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol. 2019;12:159-171. https://www.tandfonline.com/doi/abs/10.1080/17474086.2019.1585239?journalCode=ierr20
Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Treat Res. 2019;179:159-178. https://link.springer.com/chapter/10.1007%2F978-3-030-20315-3_11
Santoro M, Accurso V, Mancuso S, et al. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. Hematol Oncol. 2019;37:434-437. https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2670
Silver RT, Krichevsky S. Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. Haematologica. 2019;104:2200-2205. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821600/
Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9
Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext
Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135-2144. https://www.nejm.org/doi/full/10.1056/NEJMcp1816082?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133-143. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25303
Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019;94:5-9. https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25294
Tremblay D, Putra J, Vogel A, et al. The Implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/
Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-1509. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000428
Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/

2018

Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018:blood-2018-02-834820.
Peeken JC, Jutzi JS, Wehrle J, et al. Two novel epigenetic pathways regulate NFE2 overexpression in myeloproliferative neoplasms. Blood. 2018:blood-2017-10-810622.
Elf S, Abdelfattah NS, Baral AJ, et al. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018;131(7):782-786. Epub 2017 Dec 29.
Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPN seven years after approval. Blood. 2018:blood-2018-01-791491.
Palmer J, Bruso M, Kosiorek H, et al. Views on Bone Marrow Transplant: A Survey of Patients with Myelofibrosis. Biol Blood Marrow Transplant. 2018:24(3):S325-S326. Abstract 468.
Li J, Prins D, Park HJ, et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood. 2018;131:649-661.

2017

Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130(9):1125-1131. Epub 2017 Jul 3.
Mascarenhas J, Lu M, Virtgaym E, et al. Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood. 2017;130:254.
Yue L, Bartenstein M, Zhao W, et al. Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017;2(7):e90932. Published online 2017 Apr 6.
Marchetti M, Kroeger N. Which Patients with Myelofibrosis Should Receive Allogeneic Stem Cell Transplantation? A Decision Analysis Based on the Systematic Review of 4,341 Patients. Blood. 2017;130:3301.
Mead AJ, Mullally A. Myeloproliferative Neoplasm Stem Cells. Blood. 2017:blood-2016-10-696005.
Salit RB, Deeg HJ. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? Biol Blood Marrow Transplant. 2018;24(4):649-658. Epub 2017 Nov 8.

2016

Senquan L, Williams DM, Moliterno AR, et al. Generation, Characterization and Genetic Modification of Human iPSCs Containing Calr, MPL and JAK2 Mutations Found in MPN Patients. Blood. 2016;128:3139.
Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis. BuisnessWire. December 02, 2016.
Gisslinger H, Klade C, Georgiev P, et al. Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients. Blood. 2016;128:475.
Gisslinger H, Klade C, Georgiev P, et al. Final Results from the Phase 3 Trial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status. . Blood. 2016;128:476.
Mascarenhas J, Hoffman R, Talpaz M, et al. Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl. Blood. 2016;128:LBA-5.
Mesa RA, Hoffman R, Kosiorek HE, et al. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood. 2016;128:4271.
Mascarenhas JO, Prchal JY, Rambaldi A, et al.Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood. 2016;128:479.
New MRI-focused approach to detecting myelofibrosis. HealthImaging. November 14, 2016.